Table 2.
PET Response and Change in Level of Total Plasma cfDNA in Correlation to CT Response
| CT Response⁎ |
||||
|---|---|---|---|---|
| PR | SD | PD | Total | |
| PET response using %∆SULpeak assessment† (P = .076‡) | ||||
| PMR | 0 | 3 | 2 | 5 (12%) |
| SMD | 1 | 11 | 20 | 32 (74%) |
| PMD | 0 | 0 | 6 | 6 (14%) |
| Total n (%) | 1 (2%) | 14 (33%) | 28 (65%) | 43 (100%) |
| PET response using %∆TLG assessment§ (P = .003‡) | ||||
| PMR | 1 | 4 | 1 | 6 (15%) |
| SMD | 0 | 9 | 14 | 23 (56%) |
| PMD | 0 | 0 | 12 | 12 (29%) |
| Total n (%) | 1 (2%) | 13 (32%) | 27 (66%) | 41 (100%) |
| Total plasma cfDNA (P = .172¶) | ||||
| Median %∆cfDNA (range) | 5% (−91 to 401) | 58% (−31 to 6249) | 47% (−91 to 6249) | |
| Total n (%) | 12 (40%) | 18 (60%) | 30 (100%) | |
PR, partial response; PD, progressive disease; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease.
⁎
An evaluation CT scan was performed in 44 patients. CT response was defined according to RECIST version 1.1 criteria.
†
Response was defined according to PERCIST 1.0 guideline.
‡
In calculation of the P value, PMR and SMD as well as PR and SD were combined. P value was calculated by the Fisher’s exact test.
§
PMR was defined as a reduction in TLG of minimum 25%, PMD as an increase in TLG of minimum 25%, and SMD as a change not classified as PMR or PMD.
¶
P value was calculated by the Mann-Whitney U test.